Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype

Jorgen Vestbo; Alvar Agustí; Lisa D. Edwards; Stephen I. Rennard; William MacNee; Ruth Tal-Singer; Bruce E. Miller; Jørgen Vestbo; David A. Lomas; Peter M A Calverley; Emiel Wouters; Courtney Crim; Julie C. Yates; Edwin K. Silverman; Harvey O. Coxson; Per Bakke; Ruth J. Mayer; Bartolome Celli

doi:10.1371/journal.pone.0037483

Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype

Jorgen Vestbo, Alvar Agustí, Lisa D. Edwards, Stephen I. Rennard, William MacNee, Ruth Tal-Singer, Bruce E. Miller, Jørgen Vestbo, David A. Lomas, Peter M A Calverley, Emiel Wouters, Courtney Crim, Julie C. Yates, Edwin K. Silverman, Harvey O. Coxson, Per Bakke, Ruth J. Mayer, Bartolome Celli

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). Methods and Findings: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p

Original language	English
Article number	e37483
Journal	PLoS ONE
Volume	7
Issue number	5
DOIs	https://doi.org/10.1371/journal.pone.0037483
Publication status	Published - 18 May 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0037483

http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0037483&representation=PDF

Cite this

Vestbo, J., Agustí, A., Edwards, L. D., Rennard, S. I., MacNee, W., Tal-Singer, R., Miller, B. E., Vestbo, J., Lomas, D. A., Calverley, P. M. A., Wouters, E., Crim, C., Yates, J. C., Silverman, E. K., Coxson, H. O., Bakke, P., Mayer, R. J., & Celli, B. (2012). Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype. PLoS ONE, 7(5), Article e37483. https://doi.org/10.1371/journal.pone.0037483

@article{62bccb09df5e443e8d405ee01d73dfc6,

title = "Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype",

abstract = "Background: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). Methods and Findings: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p",

author = "Jorgen Vestbo and Alvar Agust{\'i} and Edwards, {Lisa D.} and Rennard, {Stephen I.} and William MacNee and Ruth Tal-Singer and Miller, {Bruce E.} and J{\o}rgen Vestbo and Lomas, {David A.} and Calverley, {Peter M A} and Emiel Wouters and Courtney Crim and Yates, {Julie C.} and Silverman, {Edwin K.} and Coxson, {Harvey O.} and Per Bakke and Mayer, {Ruth J.} and Bartolome Celli",

year = "2012",

month = may,

day = "18",

doi = "10.1371/journal.pone.0037483",

language = "English",

volume = "7",

journal = "PLoS ONE",

publisher = "Public Library of Science",

number = "5",

}

Vestbo, J, Agustí, A, Edwards, LD, Rennard, SI, MacNee, W, Tal-Singer, R, Miller, BE, Vestbo, J, Lomas, DA, Calverley, PMA, Wouters, E, Crim, C, Yates, JC, Silverman, EK, Coxson, HO, Bakke, P, Mayer, RJ & Celli, B 2012, 'Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype', PLoS ONE, vol. 7, no. 5, e37483. https://doi.org/10.1371/journal.pone.0037483

TY - JOUR

T1 - Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype

AU - Vestbo, Jorgen

AU - Agustí, Alvar

AU - Edwards, Lisa D.

AU - Rennard, Stephen I.

AU - MacNee, William

AU - Tal-Singer, Ruth

AU - Miller, Bruce E.

AU - Vestbo, Jørgen

AU - Lomas, David A.

AU - Calverley, Peter M A

AU - Wouters, Emiel

AU - Crim, Courtney

AU - Yates, Julie C.

AU - Silverman, Edwin K.

AU - Coxson, Harvey O.

AU - Bakke, Per

AU - Mayer, Ruth J.

AU - Celli, Bartolome

PY - 2012/5/18

Y1 - 2012/5/18

N2 - Background: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). Methods and Findings: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p

AB - Background: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). Methods and Findings: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p

U2 - 10.1371/journal.pone.0037483

DO - 10.1371/journal.pone.0037483

M3 - Article

C2 - 22624038

VL - 7

JO - PLoS ONE

JF - PLoS ONE

IS - 5

M1 - e37483

ER -

Persistent systemic inflammation is associated with poor clinical outcomes in copd: A novel phenotype

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this